TSBX
Income statement / Annual
Last year (2023), Turnstone Biologics Corp.'s total revenue was $19.31 M,
a decrease of 73.66% from the previous year.
In 2023, Turnstone Biologics Corp.'s net income was -$55.20 M.
See Turnstone Biologics Corp.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$19.31 M
|
$73.30 M
|
$101.29 M
|
| Cost of Revenue |
$2.80 M |
$2.20 M |
$2.01 M |
| Gross Profit |
$16.51 M |
$71.10 M |
$99.28 M |
| Gross Profit Ratio |
0.85 |
0.97 |
0.98 |
| Research and Development
Expenses |
$60.49 M
|
$86.70 M
|
$54.75 M
|
| General & Administrative
Expenses |
$17.85 M
|
$18.22 M
|
$13.55 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$17.85 M
|
$18.22 M
|
$13.55 M
|
| Other Expenses |
$3.55 M |
$933,000.00 |
$708,000.00 |
| Operating Expenses |
$78.34 M |
$104.93 M |
$68.30 M |
| Cost And Expenses |
$78.34 M |
$104.93 M |
$68.30 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2.80 M
|
$2.20 M
|
$2.01 M
|
| EBITDA |
-$56.23 M
|
-$27.73 M
|
$34.38 M
|
| EBITDA Ratio |
-2.91 |
-0.38 |
0.34 |
| Operating Income Ratio
|
-3.06
|
-0.43
|
0.33
|
| Total Other
Income/Expenses Net |
$3.55 M
|
$933,000.00
|
$708,000.00
|
| Income Before Tax |
-$55.49 M |
-$30.69 M |
$33.70 M |
| Income Before Tax Ratio
|
-2.87
|
-0.42
|
0.33
|
| Income Tax Expense |
-$286,000.00 |
$141,000.00 |
$432,000.00 |
| Net Income |
-$55.20 M |
-$30.83 M |
$33.27 M |
| Net Income Ratio |
-2.86 |
-0.42 |
0.33 |
| EPS |
-4.77 |
-1.39 |
1.5 |
| EPS Diluted |
-4.77 |
-1.39 |
1.5 |
| Weighted Average Shares
Out |
$11.56 M
|
$22.19 M
|
$22.19 M
|
| Weighted Average Shares
Out Diluted |
$11.56 M
|
$22.19 M
|
$22.19 M
|
| Link |
|
|
|
